Stockscreener 앱 받기
23.72
3.22%
0.74
시간 외 거래:
23.72
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Insider sales and option exercises reported for BCAX (NASDAQ: BCAX) - Stock Titan
History Review: Is Bicara Therapeutics Incs growth already priced inOptions Play & Technical Buy Zone Confirmation - baoquankhu1.vn
CEO Moves: How liquid is Bicara Therapeutics Inc stockWeekly Risk Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
BCAX PE Ratio & Valuation, Is BCAX Overvalued - Intellectia AI
Published on: 2026-04-10 20:40:14 - baoquankhu1.vn
Trading Recap: How is Bicara Therapeutics Inc managing supply chain issues2026 Retail & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Bicara Therapeutics stock hits 52-week high at 21.99 USD By Investing.com - Investing.com Australia
Bicara Therapeutics stock hits 52-week high at 21.99 USD - Investing.com
T. Rowe Price lists 10.1% of Bicara Therapeutics (NASDAQ: BCAX) in 13G/A - Stock Titan
Bicara Therapeutics Inc. (BCAX) stock price, news, quote and history - Yahoo Finance UK
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade - MSN
Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month HighHere's Why - MarketBeat
A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration - Yahoo Finance
Bicara Therapeutics’ Earnings Call Highlights Pivotal Pivot - TipRanks
JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? - AOL.com
BCAX Technical Analysis & Stock Price Forecast - Intellectia AI
A Look At Bicara Therapeutics (BCAX) Valuation After Analyst Upgrades And Clinical Progress News - Sahm
Bicara Therapeutics Inc. (BCAX) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Bicara Therapeutics (BCAX) Is Up 13.5% After Breakthrough Status And Equity Raise Strengthen Cash Runway – Has The Bull Case Changed? - simplywall.st
Bicara Therapeutics Announces Inducement Grant - National Today
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara Therapeutics Inc. common stock (NASDAQ:BCAX) Q4 2025 earnings call transcript - MSN
HC Wainwright Has Bullish Estimate for BCAX Q1 Earnings - MarketBeat
Bicara Therapeutics stock hits 52-week high, reaching $20.42 By Investing.com - Investing.com South Africa
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year? - qz.com
Wall Street experts predict that Bicara Therapeutics Inc. (BCAX) has the potential to surge by 54.85%: Strategies for Trading - Bitget
Is CareCloud (CCLD) Performing Better Than Other Medical Stocks This Year? - Bitget
Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High Following Analyst Upgrade - MarketBeat
Bicara Therapeutics stock hits 52-week high, reaching $20.42 - Investing.com
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail
Bicara Therapeutics to rally around 121%? Here are 10 top analyst forecasts for Tuesday - MSN
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement (NASDAQ:BCAX) - Seeking Alpha
BCAX SEC FilingsBicara Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at The Goldman Sachs Group - MarketBeat
Wells Fargo Maintains Rating on BCAX, Increases Price Target to - GuruFocus
Bicara Therapeutics (NASDAQ:BCAX) Given "Outperform" Rating at Wedbush - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at Wells Fargo & Company - MarketBeat
Citizens Jmp Reiterates "Market Outperform" Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
BCAX Receives Updated Price Target from HC Wainwright & Co. | BC - GuruFocus
Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
HC Wainwright Increases Bicara Therapeutics (NASDAQ:BCAX) Price Target to $42.00 - MarketBeat
Bicara Therapeutics Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance
H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress - Investing.com UK
H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress By Investing.com - Investing.com South Africa
Citizens reiterates Bicara Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com UK
2.69%
0.25%
자본화:
|
볼륨(24시간):